Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (441-450 of 464) with videos related to

Pageof 47
Sort By:
Journal of Crohn'S & Colitis|December 8, 2017
Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary ConsensusAndrew H Kim, Charlotte Roberts, Brian G Feagan, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Gut|May 6, 2021
International consensus to standardise histopathological scoring for small bowel strictures in Crohn's diseaseIlyssa O Gordon, Dominik Bettenworth, Arne Bokemeyer, et al.
Gastroenterology|February 21, 2021
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical TrialsChristopher Ma, Rocio Sedano, Ahmed Almradi, et al.
Nature Reviews. Gastroenterology & Hepatology|June 3, 2024
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practiceDominik Bettenworth, Mark E Baker, Joel G Fletcher, et al.
Gastrointestinal Endoscopy|February 5, 2022
Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitisChristopher Ma, Albert J Bredenoord, Evan S Dellon, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
BMJ Open Gastroenterology|February 9, 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trialVipul Jairath, Guangyong Zou, Zhongya Wang, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Clinical and Translational Gastroenterology|November 3, 2017
Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter StudyLiset Westera, Tanja van Viegen, Jenny Jeyarajah, et al.
Pageof 47

Showing results (441-450 of 464) with videos related to

Sort By:
Pageof 47
Journal of Crohn'S & Colitis|December 8, 2017
Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary ConsensusAndrew H Kim, Charlotte Roberts, Brian G Feagan, et al.
Lancet (London, England)|June 6, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G Feagan, Silvio Danese, Edward V Loftus, et al.
Gut|May 6, 2021
International consensus to standardise histopathological scoring for small bowel strictures in Crohn's diseaseIlyssa O Gordon, Dominik Bettenworth, Arne Bokemeyer, et al.
Gastroenterology|February 21, 2021
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical TrialsChristopher Ma, Rocio Sedano, Ahmed Almradi, et al.
Nature Reviews. Gastroenterology & Hepatology|June 3, 2024
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practiceDominik Bettenworth, Mark E Baker, Joel G Fletcher, et al.
Gastrointestinal Endoscopy|February 5, 2022
Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitisChristopher Ma, Albert J Bredenoord, Evan S Dellon, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
BMJ Open Gastroenterology|February 9, 2024
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trialVipul Jairath, Guangyong Zou, Zhongya Wang, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Clinical and Translational Gastroenterology|November 3, 2017
Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter StudyLiset Westera, Tanja van Viegen, Jenny Jeyarajah, et al.
Pageof 47